National Neuromuscular Lecture Series Provides Training Opportunity for Neuromuscular Clinical Fellows
The NMD4C curriculum working group is pleased to share that the inaugural “National Neuromuscular Lecture Series” kicked off this August 12, 2022.
About the Series
This year-long training curriculum for current Canadian neuromuscular fellows has been developed in consultation with the directors of fellowship programs across Canada. The group decided on 41 topics which constitute a comprehensive neuromuscular knowledge base and identified subject-matter experts from across the country to deliver the weekly lectures. The lecture series is designed to offer neuromuscular fellows at Canadian institutions the chance to learn from experts in different disciplines of neuromuscular medicine and forge connections with senior clinicians and investigators from across the country. This lecture series is supplementary to the training and teaching done at each institution.
Format of the Series
The 1-hour lectures are designed with live virtual attendance in mind as the discussion with presenters and colleagues provide valuable experiences. To ensure that all fellows have access to these learning materials, a recording of each lecture is made available on a secure learning platform, which also provides an opportunity to engage in a weekly discussion forum.
To learn more about this lecture series, please contact the curriculum working group lead Dr. Hernan Gonorazky, or NDM4C Communications Coordinator, Lola Owoeye!
Ongoing Neuromuscular Curriculum Work
The launch of this lecture series comes soon after the Royal College of Physicians and Surgeons of Canada’s approval of an Area of Focused Competency in Neuromuscular Medicine, an accreditation that establishes a national standard for training and specialist competence, provides neuromuscular fellows with additional opportunities to acquire nationally and internationally portable credentials, and will help to centralize specialty training, care, and practice by providing credentials in the highly focused area of neuromuscular practice.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.